Status:
UNKNOWN
Does 3 Months Therapy With Vitamin D + Peg + Ribavirin Improve Sustained Virologic Response (SVR) in Genotype 2, 3 Chronic Hepatitis C Patients?
Lead Sponsor:
Ziv Hospital
Conditions:
Chronic Hepatitis C
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Standard therapy for chronic hepatitis C virus (HCV) is (Peg/RBV) combination therapy obtaining sustained virologic response (SVR) in 80% of naïve patients with genotype 2,3. Studies rarely address th...
Detailed Description
Standard therapy for chronic hepatitis C virus (HCV) is (Peg/RBV) combination therapy obtaining sustained virologic response (SVR) in 80% of naïve patients with genotype 2, 3. Studies rarely address t...
Eligibility Criteria
Inclusion
- 18 to 65 years of age
- chronic genotype 2,3 HCV infection
- treatment Naive negative sero for HBV, HDV and HIV viral infections
- absolute neutrophil count of \>1500 per cubic millimeter
- a platelet count of \>90,000 per cubic millimeter normal hemoglobin level
Exclusion
- decompensated liver disease (cirrhosis with CP score \>9)
- another cause of clinically significant liver disease hepato cellular carcinoma
- psychiatric Disorder
- chronic heart failure
- pregnant women
- uncontrolled diabetes with retinopathy Arrhythmia Active CAD
- positive sero for HBV, HDV and HIV viral infections or other autoimmune liver disease
Key Trial Info
Start Date :
August 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2012
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT01151397
Start Date
August 1 2011
End Date
July 1 2012
Last Update
April 28 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ziv medical center liver unit
Safed, Israel, Israel, 13100